TP53 and neoplasm: The interaction between DYRK2 and the tumor suppressor p53 phosphorylation substrate has also been revealed to be of high interest in managing human brain tumors; the main argument is that p53 decreased in 84% of glioblastoma patients and 94% of total tumor brain cell lines [14].